|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||60.68 - 61.07|
|52 Week Range||47.91 - 61.07|
|PE Ratio (TTM)||N/A|
|Expense Ratio (net)||0.60%|
Mylan (MYL), which has a global presence, is focused on developing, manufacturing, and distributing generic, brand name, and over-the-counter products in various therapeutic categories. Mylan operates a vertically integrated manufacturing platform. Of the 22 analysts covering Mylan in December 2017, 14 assigned it a “buy” or higher rating, and eight recommended “hold.” The mean rating for the stock is 2.1, and its mean target price is $44.10.
First Trust Advisors L.P. announces the declaration of distributions for 108 exchange-traded funds advised by FTA.
The best YTD performance among U.S. large-cap diversified stock ETFs was turned in by those tracking the Nasdaq 100 index.
Exchange traded funds tracking the Nasdaq 100 led U.S. diversified stock as the tech-heavy index powered to record highs.
The Zacks Analyst Blog Highlights: PowerShares QQQ, First Trust NASDAQ-100 Equal Weighted Index Fund, Fidelity Nasdaq Composite Index Tracking Stock, ProShares Ultra QQQ and ProShares UltraPro QQQ
Thanks to the surging technology sector and broad market rally, the Nasdaq Composite Index topped the major milestone of 6,000 for the first time.
First Trust Advisors L.P. announces the declaration of distributions for 91 exchange-traded funds advised by FTA.